Clinical Edit Criteria Proposal

Drug/Drug Class:	**SSRI Clinical Edit**
Date:	**December 8, 2010**
Prepared for:	
Prepared by:	**MO HealthNet**

☐ **New Criteria** ☒ **Revision of Existing Criteria**

Executive Summary

Purpose:

Ensure appropriate and prudent use SSRI antidepressants medications within the MO HealthNet Pharmacy program.

Why was this Issue Selected:

Patient safety is at the heart of MO HealthNet administration and Pharmacy management decision-making. Protecting patient safety in the Pharmacy program includes assessing for utilization of the selective serotonin reuptake inhibitor (SSRI) antidepressants. By using medical evidence guidelines, a new clinical edit can help to flag potentially dangerous duplicate and high dose therapy for these agents. Additionally, some participants are cared for by multiple prescribers and have medications filled at different pharmacies. Without a clinical edit capability it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. The clinical edit would not replace medical practice. T**he edit helps to provide an "early warning alert" to the pharmacist filling the prescription and the prescribing physician.** Even if the edit is "triggered" and the physician wishes to over-ride the process for medically necessary reasons, as is presently true for all other drug classes the drug can be approved with further medical input through direct communication with the MHD Hotline. As the clinical edits are phased in, compliance and efficacy with existing medications are always taken into account, helping to ensure a smooth transition for current participants.

Setting & Population: All Patients

Type of Criteria:

☐ **Increased risk of ADE** ☐ **Non-Preferred Agent**

☒ **Appropriate Utilization** ☐ **Other:**

Data Sources:

☐ **Only administrative databases** ☒ **Databases + Prescriber-supplied**

Program-specific information:



Setting & Population

- Drug/drug class for review: SSRI Antidepressants
- Age range: All patients
- Gender: males and females

Approval Criteria

Reference Products: Fluoxetine, Citalopram, Sertraline, and Paroxetine

- Documented compliance on current non-reference therapy
- Document ADE/ADR to reference products
- Documented adequate initial therapeutic intervention with 1 or more reference products
- Appropriate diagnosis (see diagnosis table – Appendix A)
- Doses not exceeding recommended maximum doses (see Table 1)
- Documented compliance to current therapy regimen (adults – 90 days of therapy out of the most recent 120 days)

Approval Diagnoses (Appendix A)

Condition	Submitted ICD-9 Diagnoses	Inferred Drugs	Date Range	Client Approval
Depression	311, 309.0-309.4, 289.0,300.4	--	720 days	
Bipolar	296.0 – 296.99	--	720 days	
Anorexia Nervosa	307.1	--	720 days	
Anxiety	300.00	--	720 days	
Autism	299.0 – 299.9	--	720 days	
Bulimia Nervosa	307.51	--	720 days	
Obsessive Compulsive Disorder	301.4, 300.3	--	720 days	
Panic Disorder	300.01		720 days	
Premenstrual Dysphoric Disorder (PMDD)	625.4		720 days	
Post-Traumatic Stress Disorder	309.81		720 days	
Schizophrenia	295.0 – 295.9	--	720 days	

Denial Criteria

- Use of greater than 2 SSRI antidepressants prescribed concurrently for more than 90 days.
- For under 18 years:
  - Use of more than 2 SSRI antidepressants for more than 30 days
- Use of SSRI antidepressants for children under age 5 years
- Use of SSRI antidepressants at higher than recommended max dose for more than 45 days (see Table 1)
- Concurrent use of more than 1 SNRI agent **and 1 SSRI agent** for more than 30 days
- Lack of compliance to non-reference SSRI therapy
- Lack of adequate initial therapeutic intervention with reference product(s)

Required Documentation

Laboratory results:	☐	Progress notes:	☐
MedWatch form:	☐		

Disposition of Edit

- **Denial:** Edit 682 "Clinical Edit"

References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2010.
2. Facts and Comparisons; 2010.
3. USPDI, Micromedex, 2010.
4. Clinical Pharmacology Online, 2010.
5. Missouri Behavioral Pharmacy Management Program, CNS/CMT; 2009.

SSRI Antidepressant Table 1

Brand Name	Generic Name	Adult Max Daily Dose
Celexa	Citalopram	80mg
Lexapro	Escitalopram	30mg
Prozac	Fluoxetine	90mg
Luvox	Fluvoxamine	400mg
Paxil/Pexeva	Paroxetine	75mg
Paxil CR	Paroxetine	75mg
Zoloft	Sertraline	250mg